应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
NVO 诺和诺德
交易中 02-26 11:37:35 EST
37.70
-0.46
-1.22%
最高
38.07
最低
37.33
成交量
1,600万
今开
37.84
昨收
38.16
日振幅
1.94%
总市值
1,673亿
流通市值
1,202亿
总股本
44.39亿
成交额
6.04亿
换手率
0.50%
流通股本
31.88亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
口服版司美格鲁肽大降价，诺和诺德“死磕”礼来
健识局 · 02-26 20:32
口服版司美格鲁肽大降价，诺和诺德“死磕”礼来
礼来公司表示，在2型糖尿病试验中，其口服GLP-1药物Orforglipron在血糖控制和减重方面均优于诺和诺德的口服司
格隆汇 · 02-26 19:34
礼来公司表示，在2型糖尿病试验中，其口服GLP-1药物Orforglipron在血糖控制和减重方面均优于诺和诺德的口服司
两天两笔重磅交易：GLP-1战场风云突变，巨头加速“买买买”
21世纪经济报道 · 02-26 16:11
两天两笔重磅交易：GLP-1战场风云突变，巨头加速“买买买”
GLP—1 下半场生变：辉瑞抢跑 诺和诺德与药王渐行渐远？
华夏时报网 · 02-26 14:03
GLP—1 下半场生变：辉瑞抢跑 诺和诺德与药王渐行渐远？
21亿美元！诺和诺德联手Vivtex
药视声Medispace · 02-26 13:02
21亿美元！诺和诺德联手Vivtex
头对头未达预期，诺和诺德仍有后手…
药渡 · 02-26 07:31
头对头未达预期，诺和诺德仍有后手…
这四张图表展示了诺和诺德当前的困境规模
老虎资讯综合 · 02-25 23:29
这四张图表展示了诺和诺德当前的困境规模
诺和诺德(NVO.US)斥资最高21亿美元携手Vivtex，加码下一代口服减肥药
智通财经 · 02-25 21:42
诺和诺德(NVO.US)斥资最高21亿美元携手Vivtex，加码下一代口服减肥药
诺和诺德宣布与生物制药公司Vivtex达成合作
格隆汇 · 02-25 21:06
诺和诺德宣布与生物制药公司Vivtex达成合作
诺和诺德惊心24小时：减肥药的下一个主战场在哪？
药创新 · 02-25 18:50
诺和诺德惊心24小时：减肥药的下一个主战场在哪？
【市场】17个国谈药拟进院，独家品种霸屏
米内网 · 02-25 16:07
【市场】17个国谈药拟进院，独家品种霸屏
Tides 速递 | 24周减重19.7%！联邦制药 × 诺和诺德GLP-1/GIP/GCG 三靶点激动剂减重II期研究成功
多肽圈 · 02-25 09:26
Tides 速递 | 24周减重19.7%！联邦制药 × 诺和诺德GLP-1/GIP/GCG 三靶点激动剂减重II期研究成功
诺和诺德宣布拟进行私募配售
新浪财经 · 02-25 04:57
诺和诺德宣布拟进行私募配售
诺和诺德拟将Ozempic、Wegovy美国定价最高下调50% 礼来股价应声下跌1.2%
美股速递 · 02-24 22:37
诺和诺德拟将Ozempic、Wegovy美国定价最高下调50% 礼来股价应声下跌1.2%
诺和诺德盘中异动 早盘股价大跌2.86%报38.50美元
市场透视 · 02-24 22:32
诺和诺德盘中异动 早盘股价大跌2.86%报38.50美元
价格战打响！诺和诺德(NVO.US)明年起在美大幅下调减肥药标价 狙击礼来(LLY.US)夺回市场
智通财经 · 02-24 21:31
价格战打响！诺和诺德(NVO.US)明年起在美大幅下调减肥药标价 狙击礼来(LLY.US)夺回市场
礼来盘前下跌 诺和诺德将下调Ozempic和Wegovy在美国的价格
环球市场播报 · 02-24 20:53
礼来盘前下跌 诺和诺德将下调Ozempic和Wegovy在美国的价格
诺和诺德美股盘前下跌3%
每日经济新闻 · 02-24 20:43
诺和诺德美股盘前下跌3%
诺和诺德计划在美大幅下调减肥药标价，狙击礼来，夺回市场
老虎资讯综合 · 02-24 20:42
诺和诺德计划在美大幅下调减肥药标价，狙击礼来，夺回市场
诺和诺德将司美格鲁肽(Wegovy®)在美售价下调50%，至每月675美元。
格隆汇 · 02-24 20:35
诺和诺德将司美格鲁肽(Wegovy®)在美售价下调50%，至每月675美元。
暂无数据
公司概况
公司名称：
诺和诺德
所属市场：
NYSE
上市日期：
--
主营业务：
Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球性的医疗保健公司，也是肥胖和糖尿病护理、制造和营销包括GLP-1受体激动剂和现代胰岛素在内的医药产品的世界领先企业。总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。
发行价格：
--
{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":37.695,"timestamp":1772123854865,"preClose":38.16,"halted":0,"volume":16000211,"delay":0,"changeRate":-0.012185534591194872,"floatShares":3187922885,"shares":4439052849,"eps":3.620568,"marketStatus":"交易中","change":-0.465,"latestTime":"02-26 11:37:35 EST","open":37.84,"high":38.07,"low":37.33,"amount":604164223.310626,"amplitude":0.019392,"askPrice":37.7,"askSize":410,"bidPrice":37.69,"bidSize":1180,"shortable":3,"etf":0,"ttmEps":3.620568,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772139600000},"marketStatusCode":2,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":38.16,"dividendRate":0.045681,"preHourTrading":{"tag":"盘前","latestPrice":37.82,"preClose":38.16,"latestTime":"09:29 EST","volume":827035,"amount":31290880.80349,"timestamp":1772116199189,"change":-0.34,"changeRate":-0.00891,"amplitude":0.007075},"postHourTrading":{"tag":"盘后","latestPrice":38.09,"preClose":38.16,"latestTime":"19:59 EST","volume":1002596,"amount":38226541.5368,"timestamp":1772067596705,"change":-0.07,"changeRate":-0.001834,"amplitude":0.005765},"volumeRatio":1.114907,"optionData":{"bulkOrders":[{"symbol":"NVO","call":true,"expireDate":1832043600000,"strike":"80.0","timestamp":1772118046346,"price":2.53,"volume":2550,"amount":645150,"type":"-"},{"symbol":"NVO","call":true,"expireDate":1772168400000,"strike":"40.5","timestamp":1772116202730,"price":0.08,"volume":1081,"amount":8648,"type":"-"}]},"impliedVol":0.496,"impliedVolPercentile":0.4343},"requestUrl":"/m/hq/s/NVO/tweets","defaultTab":"tweets","newsList":[{"id":"2614417340","title":"口服版司美格鲁肽大降价，诺和诺德“死磕”礼来","url":"https://stock-news.laohu8.com/highlight/detail?id=2614417340","media":"健识局","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614417340?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:32","pubTimestamp":1772109125,"startTime":"0","endTime":"0","summary":"2月26日，青海省药品采购中心发布《关于调整部分药品价格的通知》，口服司美格鲁肽片剂出现在降价名单中。司美格鲁肽原定中国市场的专利到期在即，而礼来的替尔泊肽在全球市场已经超过司美格鲁肽全系产品。诺和诺德最有优势的是口服版司美格鲁肽，也面临对手紧咬不放。今年3月，司美格鲁肽各类剂型的核心专利将在国内到期，也包括口服制剂。在这样的局面下，诺和诺德把口服司美格鲁肽的价格降下来，相当于给行业定调。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226203456a7227c99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226203456a7227c99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1983299246.USD","SGXZ31699556.SGD","BK4581","LU2491049909.HKD","SG9999014914.USD","LU0385154629.USD","BK4007","LU2750360997.AUD","IE00BJJMRX11.SGD","LU2168564149.EUR","LU0823434740.USD","LU0471298694.HKD","LU0787776722.HKD","LLY","BK4599","IE0005OL40V9.USD","LU2236285917.USD","LU2471134523.USD","LU2896262040.SGD","LU2112291526.USD","LU0354030511.USD","IE00BFTCPJ56.SGD","LU2089984988.USD","LU0417517546.SGD","LU1917777945.USD","LU1988902786.USD","SG9999013999.USD","LU2237438978.USD","LU0256863811.USD","LU2023250330.USD","SG9999014906.USD","IE0009355771.USD","IE00BJT1NW94.SGD","SG9999017495.SGD","LU1989771016.USD","LU0640476718.USD","LU2361044949.HKD","LU2552382058.USD","IE0004445239.USD","LU0820561909.HKD","IE00B4JS1V06.HKD","LU0096364046.USD","SG9999015945.SGD","LU0786609619.USD","LLYX","LU2237443465.HKD","LU1548497426.USD","LU0114720955.EUR","LU0820561818.USD","LU0079474960.USD","LU1280957306.USD","LU2237443895.HKD","LU0323591593.USD","LU2028103732.USD","LU2552382215.SGD","SG9999015978.USD","LU2237443978.SGD","LU2211815571.USD","SG9999001176.SGD","IE00BZ1G4Q59.USD","LU2461242641.AUD","LU0158827781.USD","IE00B775H168.HKD","LU1267930730.SGD","SG9999014880.SGD","LU0471298777.SGD","LU2324357040.USD","LU2168563687.JPY","LU1720051017.SGD","LU2265009873.SGD","LU1551013425.SGD","LU0456855351.SGD","NVOX","SGXZ99366536.SGD","LU2237443622.USD","LU0238689110.USD","LU2756315318.SGD","BK4534","LU2168564065.EUR","LU0097036916.USD","LU1868836591.USD","LU2456880835.USD","LU0154236417.USD","LU2357305700.SGD","LU0122379950.USD","LU0289739699.SGD","LU1093756168.USD","LU2491050154.USD","LU2271345857.HKD","LU2089284900.SGD","LU0823434583.USD","LU0683600562.USD","LU0320765992.SGD","LU0256863902.USD","LU2491050071.SGD","IE0004445015.USD","IE00BFSS7M15.SGD","LU2417539215.USD","LU0320765059.SGD","IE00BFSS8Q28.SGD","IE00BKVL7J92.USD","LU0889565916.HKD","LU0061475181.USD","IE00BKPKM429.USD","BK4585","LU2111349929.HKD","LU2023251221.USD","SG9999001176.USD","LU1291159041.SGD","LU1232071149.USD","LU1974910355.USD","LU2264538146.SGD","ELIS","LU2746668461.USD","IE00B1XK9C88.USD","LU0225283273.USD","IE00BJJMRZ35.SGD","LU0354030438.USD","LU1069344957.HKD","LU1868837300.USD","IE00BJLML261.HKD","LU2237443549.SGD","LU2168564222.USD","LU2750360641.GBP","SGXZ57979304.SGD","LU2213496289.HKD","LU0316494557.USD","LU0234572021.USD","BK4533","LU1712237335.SGD","LU1868837136.USD","LU2063271972.USD","LU2108987350.USD","IE0002141913.USD","LU0882574055.USD","LU1061106388.HKD","LU2471134952.CNY","LU0203201768.USD","IE0001KFT4U8.USD","LU0210536198.USD","LU1720051108.HKD","IE00BWXC8680.SGD","LU0094547139.USD","LU2552382132.HKD","LU0708995401.HKD","LU2023250504.SGD","IE00B4R5TH58.HKD","LU0353189763.USD","IE00BKDWB100.SGD","LU1804176565.USD","LU1623119135.USD","LU2746668974.SGD","LU1323610961.USD","LU0158827948.USD","LU1868836757.USD","LU0432979614.USD","LU1145028129.USD","SG9999015986.USD","LU0058720904.USD","LU1629891620.HKD","LU1064131342.USD","LU2462157665.USD","GB00BDT5M118.USD","LU1868836914.USD","LU0109394709.USD","LU2361045086.USD","LU1023059063.AUD","LU2756315664.SGD","IE00B7KXQ091.USD","LU2089283258.USD","SG9999018857.SGD","LU2360106947.USD","LU2168564495.EUR","NVOH","LU0672654240.SGD","LU2468319806.SGD","LU2361044865.SGD","NVO","LU1551013342.USD","LU2106854487.HKD","LU1093756325.SGD","BK4516","SG9999015952.SGD","SGXZ81514606.USD","IE00BK4W5L77.USD","LU1127390331.HKD","LU2087625088.SGD","ELIL","LU0266013472.USD","LU0006306889.USD","LU2471134879.HKD","LU0106261372.USD","LU1814569148.SGD","LLYZ","SG9999018865.SGD","IE00BK4W5M84.HKD","LU0820562030.AUD","LU0109391861.USD","LU0943347566.SGD","LU0466842654.USD","BK4588","LU2237443382.USD","LLII","LU2602419157.SGD","LU0964807845.USD","BK4532","IE00B2B36J28.USD","IE00BJJMRY28.SGD","SG9999014898.SGD","LU0689472784.USD","LU0203202063.USD","LU0353189680.USD","LU0882574139.USD","LU1057294990.SGD","LU1035775433.USD","IE00BN29S564.USD","LU0823416689.USD","LU1366192091.USD","LU2471134796.USD","SGXZ51526630.SGD","IE00B1BXHZ80.USD","LU0198837287.USD"],"gpt_icon":1},{"id":"2614048703","title":"礼来公司表示，在2型糖尿病试验中，其口服GLP-1药物Orforglipron在血糖控制和减重方面均优于诺和诺德的口服司","url":"https://stock-news.laohu8.com/highlight/detail?id=2614048703","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614048703?lang=zh_cn&edition=full","pubTime":"2026-02-26 19:34","pubTimestamp":1772105657,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0256863811.USD","IE0005OL40V9.USD","LU0823416689.USD","LU2361045086.USD","LU2211815571.USD","LU2462157665.USD","LU2237443622.USD","LU0203201768.USD","LU1267930730.SGD","LU1868836757.USD","SG9999001176.SGD","LU0158827781.USD","LU1548497426.USD","LU2552382132.HKD","IE00BK4W5M84.HKD","IE0001KFT4U8.USD","LU2471134523.USD","IE00B1BXHZ80.USD","LU0471298694.HKD","IE0002141913.USD","LU0122379950.USD","LU1127390331.HKD","BK4516","BK4007","LU2357305700.SGD","LU2089283258.USD","LU0256863902.USD","LU2112291526.USD","BK4590","LU2361044865.SGD","LLY","LU1804176565.USD","BK4534","LU0079474960.USD","SG9999001176.USD","LU0787776722.HKD","LU0320765992.SGD","LU1093756168.USD","IE00BKPKM429.USD","LU0432979614.USD","LU1623119135.USD","BK4532","LU0964807845.USD","LU1917777945.USD","LU0289739699.SGD","LU2491050071.SGD","IE00BK4W5L77.USD","LU0820562030.AUD","LU0471298777.SGD","LU1629891620.HKD","LU2168564222.USD","LU2237438978.USD","LU0234572021.USD","ELIL","IE00BJT1NW94.SGD","LU0882574055.USD","LU1061106388.HKD","LU1023059063.AUD","SG9999015945.SGD","ELIS","LU2552382058.USD","LU2471134796.USD","LLII","IE00BKVL7J92.USD","LU0266013472.USD","GB00BDT5M118.USD","LU1057294990.SGD","IE00BKDWB100.SGD","LU0210536198.USD","LU2552382215.SGD","LU0097036916.USD","LU1868837136.USD","LU0225283273.USD","LU1868836914.USD","LU1868837300.USD","IE0004445239.USD","LU0061475181.USD","LU1366192091.USD","LU2168564495.EUR","LU1093756325.SGD","IE00B7KXQ091.USD","LU1983299246.USD","IE00BWXC8680.SGD","BK4581","LU2746668974.SGD","LU0154236417.USD","LU2028103732.USD","BK4533","LU0094547139.USD","IE00B2B36J28.USD","LU2063271972.USD","LU0943347566.SGD","IE0009355771.USD","LU0889565916.HKD","LU0006306889.USD","LU0203202063.USD","NVO","LU0823434583.USD","LU0316494557.USD","SG9999014880.SGD","LU2213496289.HKD","SGXZ57979304.SGD","LU0353189680.USD","LU2111349929.HKD","LU0106261372.USD","LU2237443895.HKD","LU1988902786.USD","IE00B1XK9C88.USD","SG9999014914.USD","LU0198837287.USD","IE00BN29S564.USD","SG9999015986.USD","LU0820561909.HKD","LU1712237335.SGD","LU2265009873.SGD","SG9999013999.USD","IE00B4R5TH58.HKD","LU2461242641.AUD","IE00BJJMRZ35.SGD","SG9999018857.SGD","LU0238689110.USD","LU0320765059.SGD","LU0466842654.USD","SG9999018865.SGD","SGXZ99366536.SGD","LU2896262040.SGD","LU2108987350.USD","IE00BJLML261.HKD","IE0004445015.USD","LU1814569148.SGD","LU2237443382.USD","LU2750360997.AUD","BK4599","LU2236285917.USD","LU0820561818.USD","SG9999017495.SGD","BK4588","LU2361044949.HKD","IE00B775H168.HKD","LU2746668461.USD","SG9999015952.SGD","LU0823434740.USD","LU2471134879.HKD","LU0385154629.USD","LU2237443549.SGD","LU1291159041.SGD","LU2271345857.HKD","LU0683600562.USD","LU0354030438.USD","LU0109391861.USD","LU0323591593.USD","IE00BFSS8Q28.SGD","LU2360106947.USD","LU0882574139.USD","LU2471134952.CNY","BK4144","LU1989771016.USD","LU1232071149.USD","LU0456855351.SGD","LU2023251221.USD","LU1280957306.USD","LU2324357040.USD","LU0353189763.USD","LU1069344957.HKD","LU2602419157.SGD","SGXZ31699556.SGD","LU1035775433.USD","LU2237443465.HKD","SG9999014898.SGD","SG9999014906.USD","LU1323610961.USD","IE00BJJMRY28.SGD","LU2168563687.JPY","IE00BFSS7M15.SGD","IE00BZ1G4Q59.USD","LU1064131342.USD","LU1551013425.SGD","LU2756315664.SGD","SGXZ51526630.SGD","SGXZ81514606.USD","LU0672654240.SGD","LU0708995401.HKD","LU2491050154.USD","LU0354030511.USD","LU0786609619.USD","LU2023250504.SGD","LU2456880835.USD","LU2468319806.SGD","LU1720051108.HKD","BK4585","LU2087625088.SGD","LU0158827948.USD","IE00BJJMRX11.SGD","LU2417539215.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU1145028129.USD","LU0417517546.SGD","LU2089284900.SGD","LU2023250330.USD","LU0689472784.USD","LU2089984988.USD","NVOH","LU2106854487.HKD","LU2237443978.SGD","LU1720051017.SGD","LU1868836591.USD","NVOX","SG9999015978.USD","LLYZ","LLYX","LU2168564065.EUR","LU1551013342.USD","LU2264538146.SGD","LU1974910355.USD","LU0109394709.USD","LU2750360641.GBP","LU0096364046.USD","IE00B4JS1V06.HKD","LU2168564149.EUR","LU2491049909.HKD","LU2756315318.SGD","LU0114720955.EUR","LU0640476718.USD"],"gpt_icon":0},{"id":"2614018937","title":"两天两笔重磅交易：GLP-1战场风云突变，巨头加速“买买买”","url":"https://stock-news.laohu8.com/highlight/detail?id=2614018937","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614018937?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:11","pubTimestamp":1772093478,"startTime":"0","endTime":"0","summary":"两天内两笔重磅交易，背后是两个截然不同的战略逻辑，却共同指向了火热的GLP-1赛道。这笔交易的精妙之处在于其“分工”设计。过去两年间，辉瑞在GLP-1领域的自主研发进程可谓屡遭挫折。这是辉瑞在GLP-1减重药上的再次折戟。此前，辉瑞先后叫停了Danuglipron、Lotiglipron 两项口服GLP-1制剂的研究。因副作用问题，其口服小分子GLP-1药物Lotiglipron和Danuglipron的研发相继受阻，自有管线几近清零。根据新规，Ozempic和Wegovy的月定价均为675美元，自2027年1月1日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226161142a7218030&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226161142a7218030&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","IE00BZ1G4Q59.USD","BK4590","NVOH","LU1093756325.SGD","IE00BKVL7J92.USD","LU0154236417.USD","BK4532","NVOX","BK4007","BK4599","PFE","BK4144","NVO","LU1093756168.USD","BK4588"],"gpt_icon":1},{"id":"2614096039","title":"GLP—1 下半场生变：辉瑞抢跑 诺和诺德与药王渐行渐远？","url":"https://stock-news.laohu8.com/highlight/detail?id=2614096039","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614096039?lang=zh_cn&edition=full","pubTime":"2026-02-26 14:03","pubTimestamp":1772085829,"startTime":"0","endTime":"0","summary":"全球GLP—1赛道格局生变，曾经的行业霸主诺和诺德正遭遇重大危机。作为胰岛素领域巨头，诺和诺德全力研发的新一代减重药CagriSema，在头对头试验中数据不敌礼来的替尔泊肽，引发其股价狂泄，美股单日暴跌超16%，创下2021年6月以来的最低收盘纪录。更为严峻的是，双雄并立的GLP—1赛道又切入新玩家辉瑞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602263655208077.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602263655208077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","IE00BBT3K403.USD","LU1066053197.SGD","LU1066051498.USD","BK4590","PFE","LU0985481810.HKD","BK4533","SG9999002232.USD","LU0225771236.USD","NVO","SG9999001176.USD","LU1894683264.USD","LU0456855351.SGD","BK4568","SG9999003800.SGD","IE0002270589.USD","IE00BKVL7J92.USD","BK4532","NVOX","LU0306807586.USD","IE00BLSP4452.SGD","IE00B19Z3581.USD","BK4585","LU0321505868.SGD","BK4581","BK4592","LU0868494617.USD","BK4534","LU0306806265.USD","IE00BZ1G4Q59.USD","BK4599","SG9999001176.SGD","LU0170899867.USD","LU1057294990.SGD","SGXZ57979304.SGD","NVOH","LU1883839398.USD","SG9999013999.USD","LU0234572021.USD","LU1093756325.SGD","SG9999011175.SGD","LU0289739699.SGD","LU1093756168.USD","BK4550","LU1023059063.AUD","LU1894683348.USD","LU0122379950.USD","BK4144","IE000M9KFDE8.USD","LU0225284248.USD","IE00BLSP4239.USD","SG9999002224.SGD","LU0154236417.USD","LU0321505439.SGD","IE00B19Z3B42.SGD","BK4007","LU0058720904.USD"],"gpt_icon":1},{"id":"2614384091","title":"21亿美元！诺和诺德联手Vivtex","url":"https://stock-news.laohu8.com/highlight/detail?id=2614384091","media":"药视声Medispace","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614384091?lang=zh_cn&edition=full","pubTime":"2026-02-26 13:02","pubTimestamp":1772082150,"startTime":"0","endTime":"0","summary":"它联手的目标，是一家从麻省理工学院传奇实验室里走出的生物科技公司——Vivtex。雪上加霜的是，就在与Vivtex合作官宣前一日，诺和诺德备受期待的新一代复方减肥药CagriSema，在头对头三期临床试验中败下阵来。因此，与Vivtex的合作，是诺和诺德在技术源头的一次“抢滩登陆”，旨在为其下一代口服管线装上动力强劲的“引擎”，确保在未来竞争中不掉队。未来与挑战如果Vivtex的技术最终获得成功，其影响将是革命性的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226142430a4ca3757&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226142430a4ca3757&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4599","BK4585","NVOX","NVOH","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","NVO","BK4007","LU0154236417.USD","LU1093756168.USD","BK4588"],"gpt_icon":1},{"id":"2614306145","title":"头对头未达预期，诺和诺德仍有后手…","url":"https://stock-news.laohu8.com/highlight/detail?id=2614306145","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614306145?lang=zh_cn&edition=full","pubTime":"2026-02-26 07:31","pubTimestamp":1772062297,"startTime":"0","endTime":"0","summary":"正文共：1679字预计阅读时间：5分钟2026年2月23日，诺和诺德公布了一项名为REDEFINE 4的头对头试验数据。诺和诺德的“后手”尽管暂时遭遇挫折，但诺和诺德并未放弃对CagriSema的探索，并为之规划了清晰的后续开发路径。在司美格鲁肽面临替尔泊肽强力狙击、市值差距拉大的背景下，诺和诺德已将目光投向更远的未来。诺和诺德的后手仍有很多…","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226094120a4c93be5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226094120a4c93be5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","LU0154236417.USD","BK4007","NVO","BK4532","BK4585","NVOX","IE00BZ1G4Q59.USD","NVOH","LU1093756168.USD","BK4588","LU1093756325.SGD","BK4599"],"gpt_icon":1},{"id":"1105563536","title":"这四张图表展示了诺和诺德当前的困境规模","url":"https://stock-news.laohu8.com/highlight/detail?id=1105563536","media":"老虎资讯综合","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105563536?lang=zh_cn&edition=full","pubTime":"2026-02-25 23:29","pubTimestamp":1772033344,"startTime":"0","endTime":"0","summary":"诺和诺德是首家研制出用于减肥的GLP-1药物的公司，并一度成为欧洲市值最高的企业。尽管率先推出了用于减肥的GLP-1药物，但诺和诺德的市场份额已被侵蚀。诺和诺德对其面临的挑战，尤其是定价方面的挑战，有着清醒的认识。以下图表展示了诺和诺德所面临挑战的规模。诺和诺德通常被视为一家专注于糖尿病和肥胖症领域的纯业务公司。诺和诺德表示对该药物持乐观态度，并将通过进一步试验来评估其全部减肥潜力。","market":"us","thumbnail":"https://community-static.tradeup.com/news/1d88a89585f427c3418708220ab3f4d6","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/1d88a89585f427c3418708220ab3f4d6"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ce51f37ae94576c950abf1f04bdd80f4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"这四张图表展示了诺和诺德当前的困境规模","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO"],"gpt_icon":1},{"id":"2614295080","title":"诺和诺德(NVO.US)斥资最高21亿美元携手Vivtex，加码下一代口服减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=2614295080","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614295080?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:42","pubTimestamp":1772026931,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，丹麦制药商诺和诺德周三表示，已与总部位于美国的Vivtex公司达成一项价值高达21亿美元的合作协议，共同开发用于治疗肥胖症和糖尿病的下一代口服药物。据了解，此次合作的核心价值在于Vivtex所拥有的颠覆性口服给药研发平台。两家公司表示，Vivtex的平台利用肠道筛选检测、递送技术及人工智能工具，助力生物药物实现片剂化给药。诺和诺德目前提供用于治疗肥胖症和2型糖尿病的GLP-1药物，包括Wegovy、Ozempic及口服糖尿病药物Rybelsus。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ce51f37ae94576c950abf1f04bdd80f4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺和诺德(NVO.US)斥资最高21亿美元携手Vivtex，加码下一代口服减肥药","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1093756168.USD","BK4588","IE00BZ1G4Q59.USD","BK4007","BK4599","LU1093756325.SGD","NVO","NVOH","IE00BKVL7J92.USD","BK4532","BK4585","NVOX","LU0154236417.USD"],"gpt_icon":1},{"id":"2614820570","title":"诺和诺德宣布与生物制药公司Vivtex达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2614820570","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614820570?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:06","pubTimestamp":1772024794,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","BK4588","LU1093756168.USD","NVO","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4585","LU1093756325.SGD","IE00BKVL7J92.USD","NVOH","BK4007","BK4599","NVOX"],"gpt_icon":0},{"id":"2614208997","title":"诺和诺德惊心24小时：减肥药的下一个主战场在哪？","url":"https://stock-news.laohu8.com/highlight/detail?id=2614208997","media":"药创新","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614208997?lang=zh_cn&edition=full","pubTime":"2026-02-25 18:50","pubTimestamp":1772016613,"startTime":"0","endTime":"0","summary":"然而剧情在24小时内急转直上：诺和诺德携手联邦制药宣布，三受体激动剂UBT251在中国的II期减重试验大获成功。24周治疗后，受试者平均减重19.7%，相当于甩掉了17.5公斤的负担，而安慰剂组仅减轻2%。在最高剂量12mg组，retatrutide在68周时实现平均28.7%的体重下降，显著高于安慰剂组的2.1%；9mg组的减重幅度为26.4%。TRIUMPH-4的另一个特点在于其并未将减重作为唯一关注点。总体停药率在高剂量组中最高达到18.2%，其中一部分与不良反应相关，且停药率与基线BMI相关。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251955319541f51c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251955319541f51c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","NVOH","BK4599","NVOX","LU0154236417.USD","LU1093756325.SGD","LU1093756168.USD","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4585","BK4007","BK4532","BK4588"],"gpt_icon":1},{"id":"2614554709","title":"【市场】17个国谈药拟进院，独家品种霸屏","url":"https://stock-news.laohu8.com/highlight/detail?id=2614554709","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614554709?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:07","pubTimestamp":1772006826,"startTime":"0","endTime":"0","summary":"精彩内容近日，成都市第六人民医院发布招标公示，将组织拟引入药品生产企业遴选工作。17个新药在列，均为国谈药，涵盖化学药及生物药，既有环泊酚注射液等超10亿大品种，亦有芦比前列酮软胶囊、替戈拉生片等2025年前三季度销售额增速达三位数的高增长品种。17个新药均为国谈药，目前均已纳入国家医保乙类目录，主要集中在消化系统及代谢、神经系统、心脑血管系统等治疗领域，可见以慢病药、常见病药为主。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0154236417.USD","NVO","BK4532","01276","BK4599","NVOH","BK4585","NVS","LU1093756325.SGD","BK4588","IE00BKVL7J92.USD","002793","002653","IE00BZ1G4Q59.USD","NVOX","600276","BK4007","LU1093756168.USD"],"gpt_icon":1},{"id":"2614778191","title":"Tides 速递 | 24周减重19.7%！联邦制药 × 诺和诺德GLP-1/GIP/GCG 三靶点激动剂减重II期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2614778191","media":"多肽圈","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614778191?lang=zh_cn&edition=full","pubTime":"2026-02-25 09:26","pubTimestamp":1771982766,"startTime":"0","endTime":"0","summary":"｜中肽生化内容团队编辑2026年2月24日，联邦制药国际控股有限公司与Novo Nordisk A/S联合发布GLP-1/GIP/GCG三靶点受体激动剂UBT251中国II期临床研究的主要结果。诺和诺德还计划于2026年下半年启动一项针对2型糖尿病患者的UBT251的II期临床研究。基于该研究结果，联邦制药计划启动一项针对中国超重或肥胖患者的III期临床研究。2025年3月，联邦生物与诺和诺德就UBT251达成独家许可协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022509412297a6ea55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022509412297a6ea55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","NVO","03933"],"gpt_icon":1},{"id":"2614272820","title":"诺和诺德宣布拟进行私募配售","url":"https://stock-news.laohu8.com/highlight/detail?id=2614272820","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614272820?lang=zh_cn&edition=full","pubTime":"2026-02-25 04:57","pubTimestamp":1771966624,"startTime":"0","endTime":"0","summary":"诺和诺德宣布拟进行私募配售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225050815a71b1c34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225050815a71b1c34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","BK4007","LU1093756168.USD","NVOX","NVO","LU0154236417.USD","NVOH","BK4588","BK4532","BK4599","BK4585","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"1154190688","title":"诺和诺德拟将Ozempic、Wegovy美国定价最高下调50% 礼来股价应声下跌1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154190688","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154190688?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:37","pubTimestamp":1771943830,"startTime":"0","endTime":"0","summary":"据消息称，丹麦制药巨头诺和诺德计划将其明星产品Ozempic与Wegovy在美国市场的标价最高下调50%，这一举措立即在资本市场引发连锁反应。其主要竞争对手礼来的股价应声下挫1.2%，显示出市场对潜在价格战可能挤压行业利润的担忧。\n此次价格调整若属实，将显著提升诺和诺德旗下两款热门GLP-1药物在美国市场的可及性与竞争力。分析人士指出，降价策略可能旨在进一步扩大市场份额，并对礼来同类产品Mounjaro和Zepbound构成直接压力。投资者正密切关注事态发展，评估此举对全球减肥药及糖尿病治疗领域竞争格局的深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0943347566.SGD","LU1548497426.USD","LU2237443465.HKD","BK4007","IE0001KFT4U8.USD","LU0106261372.USD","LU2237443622.USD","LU2462157665.USD","IE00BJLML261.HKD","LU1267930730.SGD","IE00B1BXHZ80.USD","LU2237443978.SGD","LU0385154629.USD","IE0004445239.USD","LU0109391861.USD","LU0889565916.HKD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU0882574139.USD","LU1804176565.USD","LU1093756168.USD","LU2265009873.SGD","LU2361044865.SGD","LU0058720904.USD","LU2089284900.SGD","LU2552382215.SGD","LU1720051017.SGD","SGXZ51526630.SGD","LU0353189763.USD","LU0323591593.USD","ELIS","SG9999013999.USD","LU2106854487.HKD","SG9999001176.SGD","LU2213496289.HKD","SGXZ31699556.SGD","LU1868837300.USD","LU2324357040.USD","LU2089984988.USD","LU0466842654.USD","IE00B7KXQ091.USD","LU2552382058.USD","LU2271345857.HKD","LU1868837136.USD","LU0882574055.USD","LU0964807845.USD","LU0353189680.USD","LU2237443549.SGD","SG9999018857.SGD","LU1061106388.HKD","LU2750360997.AUD","LU1366192091.USD","LU1623119135.USD","LU2237443382.USD","LU2417539215.USD","GB00BDT5M118.USD","LU0096364046.USD","LU1868836914.USD","SG9999001176.USD","SG9999014914.USD","LU0198837287.USD","LU2491050154.USD","LU2023250504.SGD","LU0006306889.USD","LU0266013472.USD","LU2357305700.SGD","IE00BJJMRY28.SGD","LU2237438978.USD","LU1917777945.USD","LU1280957306.USD","LU0786609619.USD","SG9999015952.SGD","LU1629891620.HKD","LU0708995401.HKD","IE00B4JS1V06.HKD","IE00B775H168.HKD","SG9999014880.SGD","LU2168564149.EUR","SGXZ99366536.SGD","IE0005OL40V9.USD","LU0122379950.USD","LU0689472784.USD","LU2756315318.SGD","LU0203201768.USD","LU1069344957.HKD","LU2468319806.SGD","LU1093756325.SGD","BK4534","SGXZ57979304.SGD","NVO","IE00B2B36J28.USD","LU0234572021.USD","LU0823434583.USD","LU2111349929.HKD","IE00BN29S564.USD","SG9999017495.SGD","LU1551013425.SGD","LU0061475181.USD","LU2746668461.USD","LU2756315664.SGD","LU1868836591.USD","LU2211815571.USD","LU0683600562.USD","LU2361044949.HKD","LU2471134879.HKD","LU1712237335.SGD","LU2023251221.USD","LU0823416689.USD","LU2896262040.SGD","IE0004445015.USD","LU2087625088.SGD","LU2168564222.USD","LU0456855351.SGD","LU2471134952.CNY","LU0354030511.USD","LU2168564495.EUR","BK4533","LU0210536198.USD","LU0114720955.EUR","LU2746668974.SGD","IE00BFSS8Q28.SGD","LU0158827781.USD","LU1988902786.USD","LU2750360641.GBP","LU0471298694.HKD","BK4588","BK4516","SG9999015945.SGD","LU2108987350.USD","LU1232071149.USD","SGXZ81514606.USD","LU1983299246.USD","LU2168564065.EUR","LU0820561909.HKD","BK4581","IE00BJJMRX11.SGD","LU0097036916.USD","LU0225283273.USD","LU0238689110.USD","LU2361045086.USD","LU2168563687.JPY","IE00BJT1NW94.SGD","IE00B1XK9C88.USD","IE00BFTCPJ56.SGD","LU0256863811.USD","LU1291159041.SGD","LU0471298777.SGD","LU2491050071.SGD","LU1551013342.USD","BK4599","IE0009355771.USD","IE0002141913.USD","LLII","LU1814569148.SGD","BK4585","LU0316494557.USD","SG9999015986.USD","LU1720051108.HKD","IE00BFSS7M15.SGD","LU0787776722.HKD","LU0820561818.USD","LU0820562030.AUD","SG9999015978.USD","ELIL","LU2028103732.USD","LLY","LU2360106947.USD","SG9999014906.USD","LU2023250330.USD","LU2237443895.HKD","LU2491049909.HKD","IE00BKDWB100.SGD","LLYX","LU2089283258.USD","LU0203202063.USD","LU0289739699.SGD","LU0672654240.SGD","LU2264538146.SGD","LU1057294990.SGD","LU2456880835.USD","LU2063271972.USD","IE00BJJMRZ35.SGD","LU2112291526.USD","LU0640476718.USD","LU1064131342.USD","LU2461242641.AUD","LU1035775433.USD","LU0094547139.USD","IE00BK4W5L77.USD","LU0079474960.USD","LU0109394709.USD","LU1127390331.HKD","LU2471134523.USD","LU0256863902.USD","LU1023059063.AUD","SG9999014898.SGD","LU1145028129.USD","LU2236285917.USD","LU0354030438.USD","LLYZ","LU1868836757.USD","LU1989771016.USD","LU0417517546.SGD","SG9999018865.SGD","IE00BWXC8680.SGD","LU1974910355.USD","LU2471134796.USD","IE00BK4W5M84.HKD","LU0158827948.USD","LU1323610961.USD","LU2552382132.HKD","LU2602419157.SGD","IE00BKPKM429.USD","LU0320765059.SGD","LU0432979614.USD","LU0823434740.USD"],"gpt_icon":0},{"id":"2613748506","title":"诺和诺德盘中异动 早盘股价大跌2.86%报38.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613748506","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613748506?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:32","pubTimestamp":1771943563,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日22时32分，诺和诺德股票出现异动，股价快速下挫2.86%。截至发稿，该股报38.50美元/股，成交量737.429万股，换手率0.17%，振幅0.71%。诺和诺德股票所在的制药行业中，整体跌幅为0.30%。诺和诺德公司简介：诺和诺德在全球品牌糖尿病治疗市场中占据大约三分之一的份额，是世界上领先的糖尿病护理产品供应商。诺和诺德还拥有一个生物制药部门，专注于治疗血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224223243a71a5305&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224223243a71a5305&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4599","LU1093756325.SGD","NVOH","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4585","NVO","NVOX","BK4007","LU1093756168.USD","BK4588"],"gpt_icon":1},{"id":"2613712854","title":"价格战打响！诺和诺德(NVO.US)明年起在美大幅下调减肥药标价 狙击礼来(LLY.US)夺回市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2613712854","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613712854?lang=zh_cn&edition=full","pubTime":"2026-02-24 21:31","pubTimestamp":1771939893,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德计划于明年大幅下调旗下两款重磅药物Wegovy和Ozempic的美国官方定价，以在肥胖症治疗市场争夺更大份额。此次降价针对的是批发采购成本，这一公开标价并不反映美国市场复杂的返利体系。目前，诺和诺德正在价格方面多措并举，以提升在肥胖症领域的竞争力。新价格将于明年1月1日生效。Millar表示，公司需要现在宣布降价，以便让付款方有时间应对明年的变化。Millar强调，两次降价相互独立，并无关联。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0009355771.USD","LU0210536198.USD","LU0106261372.USD","ELIS","LU2552382058.USD","LU0417517546.SGD","LU2168564222.USD","LU1983299246.USD","LU1145028129.USD","LU2471134952.CNY","IE00BK4W5L77.USD","LU2023250504.SGD","LLYX","LU2089284900.SGD","LU0114720955.EUR","LU0289739699.SGD","LU2168563687.JPY","LU2491050071.SGD","LU0320765992.SGD","NVOX","LU0432979614.USD","LLYZ","LU1551013342.USD","LU2271345857.HKD","LU2237443549.SGD","BK4533","IE0004445239.USD","LU1917777945.USD","LU0238689110.USD","LU1720051108.HKD","SG9999013999.USD","LLII","LU0820562030.AUD","LU1061106388.HKD","IE00BJJMRZ35.SGD","LU0058720904.USD","LU2456880835.USD","LU1023059063.AUD","NVO","LU0203202063.USD","LU2602419157.SGD","ELIL","LLY","LU2168564065.EUR","LU2756315318.SGD","LU2168564149.EUR","BK4599","NVOH","BK4007","IE00BK4W5M84.HKD"],"gpt_icon":1},{"id":"2613171180","title":"礼来盘前下跌 诺和诺德将下调Ozempic和Wegovy在美国的价格","url":"https://stock-news.laohu8.com/highlight/detail?id=2613171180","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613171180?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:53","pubTimestamp":1771937580,"startTime":"0","endTime":"0","summary":"礼来股价在盘前交易中一度迅速下跌4.1%，此前据《华尔街曰报》报道，竞争对手诺和诺德计划将Ozempic和Wegovy在美国市场的定价下调至多50%。\n 《华尔街曰报》报道，上述糖尿病及减肥治疗药物自2027年1月1日起，每月定价均将调整为675美元\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-24/doc-inhnxnuf1949059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","LU0234572021.USD","LU1069344957.HKD","IE00BK4W5M84.HKD","LU0432979614.USD","LU2063271972.USD","LU0096364046.USD","LU1983299246.USD","LU2028103732.USD","IE00BKDWB100.SGD","LU0158827948.USD","LU1868837300.USD","LU1868836757.USD","LU0266013472.USD","LU0203202063.USD","LU1548497426.USD","IE0001KFT4U8.USD","IE00BKPKM429.USD","LU0316494557.USD","LU1023059063.AUD","LU1093756168.USD","LU0114720955.EUR","LU0823434583.USD","LU2087625088.SGD","LU2896262040.SGD","LU1712237335.SGD","SGXZ99366536.SGD","IE00BJJMRX11.SGD","LU0256863811.USD","IE00BFSS8Q28.SGD","LU0320765059.SGD","LU2756315664.SGD","LU2236285917.USD","LU2552382215.SGD","LU1267930730.SGD","LU2089283258.USD","LU2089984988.USD","SG9999015945.SGD","LU2360106947.USD","BK4585","LU1291159041.SGD","SG9999014914.USD","LU0106261372.USD","LU2023251221.USD","SGXZ31699556.SGD","LU0154236417.USD","IE00B4R5TH58.HKD","LU0323591593.USD","LU0708995401.HKD","LU0943347566.SGD","LU1720051108.HKD","LU2108987350.USD","LU2491049909.HKD","BK4534","LU2361044865.SGD","LU0683600562.USD","LU1804176565.USD","LU2361044949.HKD","LU0882574139.USD","SG9999015952.SGD","IE0002141913.USD","LU2168563687.JPY","SG9999014880.SGD","IE00B775H168.HKD","BK4533","IE0004445015.USD","LU1093756325.SGD","LU0320765992.SGD","SG9999014906.USD","LU2168564495.EUR","LU1280957306.USD","LU2271345857.HKD","LU2237443978.SGD","LU0353189763.USD","LU1623119135.USD","LU2168564149.EUR","IE00BWXC8680.SGD","LU0820561818.USD","LU2456880835.USD","LU2361045086.USD","LU1917777945.USD","LU2237443895.HKD","LU2471134796.USD","GB00BDT5M118.USD","LU2112291526.USD","IE00BZ1G4Q59.USD","LU2750360997.AUD","LU1989771016.USD","LU2168564065.EUR","LU1868836914.USD","IE00B1BXHZ80.USD","LU0061475181.USD","LU1057294990.SGD","SGXZ57979304.SGD","LU0198837287.USD","LU1323610961.USD","SG9999015986.USD","LU1035775433.USD","LU2746668974.SGD","BK4532","LU2750360641.GBP","IE00BK4W5L77.USD","IE00BJLML261.HKD","LU2417539215.USD","LU2491050071.SGD","SG9999001176.SGD","LU1366192091.USD","BK4599","LU0203201768.USD","LU1127390331.HKD","IE0009355771.USD","LU0006306889.USD","IE00BJJMRZ35.SGD","BK4581","LU1868837136.USD","IE0004445239.USD","LU2237443465.HKD","SG9999017495.SGD","LU2471134879.HKD","LU0094547139.USD","LU0353189680.USD","IE0005OL40V9.USD","LU0109394709.USD","LU0787776722.HKD","LU0820562030.AUD","LU0097036916.USD","IE00BJT1NW94.SGD","LU2237443382.USD","SG9999018857.SGD","LU2168564222.USD","LU0417517546.SGD","LU0122379950.USD","LU2213496289.HKD","IE00BN29S564.USD","LU0882574055.USD","LU2023250330.USD","LU0354030511.USD","LU2237443549.SGD","LU2471134523.USD","SG9999015978.USD","LU0225283273.USD","LU1551013425.SGD","LU1720051017.SGD","LU2468319806.SGD","SG9999013999.USD","IE00B7KXQ091.USD","LU0640476718.USD","LU2462157665.USD","LU0786609619.USD","LU1814569148.SGD","NVOX","LU0158827781.USD","LU2461242641.AUD","LLYX","SG9999001176.USD","LU2552382058.USD","LU0689472784.USD","LU0456855351.SGD","IE00BKVL7J92.USD","LU1974910355.USD","LU2746668461.USD","BK4516","LU1232071149.USD","LU1629891620.HKD","LU0471298777.SGD","LU2237443622.USD","LU0289739699.SGD","IE00B2B36J28.USD","SGXZ81514606.USD","LU0823434740.USD","LU0889565916.HKD","LU0672654240.SGD","LU2357305700.SGD","BK4588","ELIS","IE00B1XK9C88.USD","LLYZ","LU0820561909.HKD","LU0238689110.USD","LU2756315318.SGD","NVOH","LU0210536198.USD","IE00BFTCPJ56.SGD","LU2089284900.SGD","LU2471134952.CNY","LU0385154629.USD","LU0964807845.USD","LU0471298694.HKD","LU0823416689.USD","LLY","LU2552382132.HKD","LU0256863902.USD","ELIL","LU2023250504.SGD","LU0058720904.USD","LU0079474960.USD","LU1868836591.USD","IE00B4JS1V06.HKD","LU2602419157.SGD","LU2265009873.SGD","LU2491050154.USD","SG9999014898.SGD","LU1145028129.USD","LU2111349929.HKD","SGXZ51526630.SGD","IE00BFSS7M15.SGD","LU0354030438.USD","LU2211815571.USD","LU2324357040.USD","LU1988902786.USD","LU2237438978.USD","NVO","LU1061106388.HKD","LU2264538146.SGD","LU0466842654.USD","IE00BJJMRY28.SGD","LLII","LU2106854487.HKD","SG9999018865.SGD","LU0109391861.USD","LU1064131342.USD","LU1551013342.USD"],"gpt_icon":0},{"id":"2613711325","title":"诺和诺德美股盘前下跌3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613711325","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613711325?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:43","pubTimestamp":1771936992,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月24日，诺和诺德美股盘前下跌3%，公司将司美格鲁肽（Wegovy）在美售价下调50%，至每月675美元。每日经济新闻","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224204542a4c31745&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224204542a4c31745&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4581","IE00BKVL7J92.USD","BK4007","BK4588","BK4599","TWM","RWM","BK4534","BK4585","UWM","NVOH","LU1093756168.USD","IE00BZ1G4Q59.USD","NVO","MNQmain","TNA","IWO","NVOX","LU0154236417.USD","SRTY","BK4535","BK4550","IWN","TZA","BK4532","LU1093756325.SGD"],"gpt_icon":0},{"id":"1108091979","title":"诺和诺德计划在美大幅下调减肥药标价，狙击礼来，夺回市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1108091979","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108091979?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:42","pubTimestamp":1771936928,"startTime":"0","endTime":"0","summary":"带来更好的获取途径和更高的可负担性。","market":"us","thumbnail":"https://static.tigerbbs.com/a7bd67b6d6b09271dab6332df6a9ee65","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a7bd67b6d6b09271dab6332df6a9ee65"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","LLY"],"gpt_icon":0},{"id":"2613584719","title":"诺和诺德将司美格鲁肽(Wegovy®)在美售价下调50%，至每月675美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2613584719","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613584719?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:35","pubTimestamp":1771936542,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b9030c47a641b4d32c695499220ff2c5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0154236417.USD","IE00BZ1G4Q59.USD","BK4007","IE00BKVL7J92.USD","BK4585","LU1093756325.SGD","BK4588","LU1093756168.USD","BK4599","NVOX","NVO","NVOH","BK4532"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":-0.2249},{"period":"1month","weight":-0.4036},{"period":"3month","weight":-0.2166},{"period":"6month","weight":-0.3241},{"period":"1year","weight":-0.5804},{"period":"ytd","weight":-0.25}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.0165}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球性的医疗保健公司，也是肥胖和糖尿病护理、制造和营销包括GLP-1受体激动剂和现代胰岛素在内的医药产品的世界领先企业。总部位于丹麦，业务遍及约80个国家，产品销往约170个国家。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.120105},{"month":2,"riseRate":0.6,"avgChangeRate":0.019485},{"month":3,"riseRate":0.454545,"avgChangeRate":0.006986},{"month":4,"riseRate":0.613636,"avgChangeRate":0.01505},{"month":5,"riseRate":0.555556,"avgChangeRate":0.018382},{"month":6,"riseRate":0.688889,"avgChangeRate":0.026171},{"month":7,"riseRate":0.488889,"avgChangeRate":-0.001692},{"month":8,"riseRate":0.533333,"avgChangeRate":0.006145},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.002979},{"month":10,"riseRate":0.488889,"avgChangeRate":-0.004606},{"month":11,"riseRate":0.6,"avgChangeRate":0.026574},{"month":12,"riseRate":0.733333,"avgChangeRate":0.048757}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}